首页 | 本学科首页   官方微博 | 高级检索  
     


Renal cell carcinoma in children: a clinicopathologic study.
Authors:Paolo Indolfi  Monica Terenziani  Fiorina Casale  Modesto Carli  Gianni Bisogno  Amalia Schiavetti  Antonia Mancini  Roberto Rondelli  Andrea Pession  Alessandro Jenkner  Paolo Pierani  Paolo Tamaro  Bruno De Bernardi  Andrea Ferrari  Nicola Santoro  Maria Giuliano  Giovanni Cecchetto  Luigi Piva  Gianmarco Surico  M Teresa Di Tullio
Affiliation:Pediatric Oncology Service-Pediatric Department II, University of Napoli, Napoli, Italy. paolo.indolfi@unina2.it
Abstract:PURPOSE: To identify the prognostic factors, treatment, and outcome of children affected by renal cell carcinoma (RCC). PATIENTS AND METHODS: The series included 41 patients (18 males and 23 females) with a median age of 124 months observed at the 11 Italian Association for Pediatric Hematology and Oncology centers from January 1973 to January 2001. Clinical data, surgical notes, pathologic findings, and summaries of therapy were taken from the charts. RESULTS: Seven (17%) of the 41 patients had a papillary histology, and 34 (82.4%) had nonpapillary histology. Eighteen patients (43.9%) had stage I, one patient (2.4%) had stage II, two patients (4.8%) had stage IIIA, 10 patients (24.3%) had stage IIIB, and nine patients (21.9%) had stage IV disease. One patient had a bilateral involvement at diagnosis. Seven patients experienced disease recurrence. Lung and liver were the most common distant lesions and usually were fatal. In this study, the major factor influencing the prognosis was the stage. Event-free survival at 20 years was 53.5% for all patients. Overall survival at 20 years was 54.9% for all patients. CONCLUSION: RCC is a rare disease in children and adolescents. This neoplasm has a different clinical presentation in children compared with adults but the same outcome. In our experience, patients with localized disease could be cured by nephrectomy alone. Prospective studies in a larger number of patients are needed to confirm radiation therapy and biologic response modifiers as effective adjunct therapy in RCC stage III. The alternative therapy seems warranted in patients with advanced disease.
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号